Replies to post #24941 on Mymetics Corp (MYMX)

[steel8000]

Ok thanks bt!!so mymx will be going thru the roof!!!!$nice find!!!$$

[Staypositive1]

interesting development here.

https://www.bcm.edu/news/nih-funds-texas-health-institutes-for-hiv-research

[steel8000]

Several collaborators several partners and now we know there is going to be major news coming!!$

[bow-tie]

Merck and Baylor Medical School work together to advance the new coronary pneumonia vaccine manufacturing platform
Credit Associated Press Source: At the Associated Press 2527 0A + A -
2020
05/28
share

Read: Leading technology company Merck and Baylor College of Medicine in Houston, Texas, usa today announced further expansion of their ongoing partnership to advance the new coronary pneumonia vaccine manufacturing platform, with the aim of accelerating access to Phase I clinical trials
Merck, a leading technology company, and Baylor College of Medicine in Houston, Texas, today announced further expansion of their ongoing partnership to advance the new coronary pneumonia vaccine manufacturing platform, which aims to accelerate progress to Phase I clinical trials.

Udit Batra, a member of Merck's executive committee and chief executive of the life sciences division, said: "Vaccine manufacturing is extremely complex, so we are working together to develop a process to accelerate the manufacture of a candidate vaccine for Baylor's new coronary pneumonia. To fight this pandemic, we need to produce an unprecedented number of vaccines in a very short period of time, and we need as many methods as possible to succeed. ”

Because of the complexity and diversity of vaccine manufacturing methods, there are no standard manufacturing templates or processes, which makes vaccine production a challenge for every organization to compete for a safe and effective new coronary pneumonia vaccine. Merck worked with researchers at Baylor Medical School and texas Children's Hospital Vaccine Development Center to use their key experience with ongoing schistosomiasis vaccine collaborations to optimize production processes and advance the production of two new coronary pneumonia candidates, including the CoVRBD219-N1 candidate vaccine, which is expected to enter clinical trials later this year. Merck will help accelerate the sustainability of its large-scale manufacturing. The partnership will focus on increasing productivity, productivity, extensiveness, scalability and cost-effectiveness.

Dr. Peter Hotez and Dr. Maria Elena Bottazzi, dean of the National School of Tropical Medicine at Baylor School of Medicine and co-director of the Texas Children's Hospital Vaccine Development Center, said, " Our initial collaboration with Merck provides a very important and critical framework for our rapid validation and preparation of the production of neglected tropical disease vaccines for global use. ”

"Expanding our collaboration, including on pandemic diseases, will now enable us to accelerate the development of scalable and affordable new coronary pneumonia candidate vaccine manufacturing processes and enable them to accelerate vaccine production in low- and middle-income countries as quickly as possible," said Botaz, who heads product development activities and is vice president of baylor's National School of Tropical Medicine. ”

The Merck-Baylor team will improve the CoVRBD219-N1 vaccine candidate vaccine manufacturing platform, originally developed from 2011 to 2016, with the goal of treating SARS. In addition, they will develop a manufacturing platform for a second candidate vaccine for coronary pneumonia, reducing the time to phase 1 clinical trials. The goal of this collaboration is to develop appropriate manufacturing processes and procedures to create a scale-up approach for commissioning and subsequent industrial production.

Merck process development scientists and biomanufactive engineers, as well as researchers at the Texas Children's Hospital Vaccine Development Center, will enter into a partnership for the first time in 2018 to advance vaccine development and production and strengthen responses to outbreaks such as new corona pneumonia. By working through existing process development platforms to lay the initial foundation, teams can quickly reduce the time it takes for vaccines to enter a clinic and achieve a key goal.

All Merck press releases are sent by e-mail at the same time as they are posted on Merck's website. Please visit the www.merckgroup.com/subscribe, register online, change options or stop the service.

Baylor Medical School and Texas Children's Hospital Vaccine Development Center received FUNDing from NAID for early development of the CoVRBD219-N1 candidate vaccine, as well as the recent preliminary development of a second new coronary pneumonia candidate vaccine. In addition, Baylor and texas Children's Hospital Vaccine Development Center hope to promote the development of new coronary pneumonia candidate vaccine through alliances with PATH to support the use of vaccines in low- and middle-income countries.



About Merck

Merck is a leading technology company focused on three areas: healthcare, life sciences and high-performance materials. Approximately 57,000 employees worldwide serve Merck and are committed to creating sustainable, enjoyable lifestyles that improve the daily lives of millions of people. From advancing gene editing technology and discovering unique ways to treat the toughest diseases, to supporting smart devices, Merck is everywhere. In 2019, Merck's sales in 66 countries were EUR 16.2 billion.

Scientific exploration and responsible management are key to Merck's technological progress. This is why Merck has evolved since its founding in 1668. The founding family still holds a majority stake in publicly traded companies. Merck owns the name and brand worldwide, with the exception of the United States and Canada, where merck uses EMDSerono to run healthcare, Millipore Sigma to run its life sciences business, and EMDPerformance Materials to run its high-performance materials business.

Merck and Baylor Medical School are working together to advance the new coronary pneumonia vaccine manufacturing platform

https://news.yaozh.com/archive/30126.html
HAD TO TRANSLATE IT!! :)

[Work Harder]

Nice find

Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters

Nicolas Collin

10 Vaccine Formulation Institute, 1228 Plan-Les-Ouates, Geneva, Switzerland

and N.C. designed and performed adjuvant mouse studies.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941618/

SMNP and alum+CpG

[Work Harder]

As such, we joined Oxford University in the United Kingdom in their announcement that they laid the foundation for large-scale production of the Covid-19 vaccine candidate, ChAdOx1 nCoV-19, which leveraged our previous collaborative work to develop the manufacturing process for a rabies vaccine candidate. Our support enabled the development of the manufacturing process, which would normally take at least six months to a year, to take place in just two months’ time, saving valuable time for the vaccine developer.

We also announced an extension of our ongoing collaboration with Baylor College of Medicine in Houston, Texas, USA, which previously focused on vaccine development for tropical disease outbreaks, to now advance a vaccine manufacturing platform for Covid-19. Our joint work supports the accelerated transition to Phase I clinical trials, optimizing the production process to advance two Covid-19 vaccine candidates, including the CoV RBD219-N1 vaccine candidate originally developed to target SARS. Additionally, our new collaboration with the Massachusetts Institute of Technology’s (MIT) Center for Collective Intelligence and Community Biotechnology Initiative began with the release of a report detailing potential paths to solutions for pandemic response. The report summarizes the results of a three-week collective intelligence exercise conducted with more than 180 science, healthcare, and policy experts from around the world, which generated suggestions to combat Covid-19 via transmission control, diagnostics, and monitoring, and accelerating access to vaccines and therapies, among other technical topics.

https://www.emdgroup.com/en/annualreport/2020/management-report/fundamental-information-about-the-group/research-and-development/life-science.html

[Work Harder]

Merck KGaA teams up to advance Baylor College's potential COVID-19 vaccines

Baylor College and Texas Children's Center for Vaccine Development are also collaborating with Swiss biotech Mymetics Corp. to create a potential COVID-19 vaccine.

https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/merck-kgaa-teams-up-to-advance-baylor-college-s-potential-covid-19-vaccines-58809822

covid 50 times LOL

These results will allow Mymetics to select the formualtions that are believed to be taken into clinical development

https://www.otcmarkets.com/filing/html?id=14842380&guid=u8bnUWrAW8iZfth

[Work Harder]

3rd Wave (2021 Q2-3)

– Sanofi Pasteur (Recombinant
Protein Insect Cell)
– Merck & Co (Live VSV)
– Baylor-BioE (Recombinant yeast
protein)

https://main.ccghe.net/sites/default/files/assets/documents/COVID19%20GRAND%20ROUNDS%202-2-2021.pdf

NEW PLAN

Pg 13